If you happen to encounter the covid-19 virus, it could survive for hours, even days, on your mask and possibly spread inside your home. The very thing that is supposed to protect me can become a harmful carrier," says Anandkumar, co-founder of Bugworks, a startup developing new antibiotics. Hes also a mentor to a diverse set of scientists and entrepreneurs who have come together under the aegis of Bengaluru-based startup I Shield to create antiviral products, starting with a covid-killer mask.
Co-founder and director of I Shield Ashok Vohra is former chairman of Singapore-based life sciences company Esco. Co-founder and director Jogin Desai, former CEO of multinational clinical research company Cenduit, is also the founder of cell therapy startup Eyestem. Another co-founder Nitish Sathyanarayanan runs a startup, Aiyon Life in Bengaluru, which is developing therapies from venom peptides. Two scientific advisors are Ram Subramanian, former director and co-founder of the Centre for Cellular and Molecular Platforms (C-CAMP) in Bengaluru, and Robert Deschenes, who chairs the department of molecular medicine at the University of South Florida.
Lab certificates
The I Shield mask has six layers. The outermost and innermost layers have a patent-pending tekFABRIK infused with an IS 212 molecule. Lab tests have shown this mask kills the SARS-CoV-2 virus responsible for the covid-19 pandemic.
The Rajiv Gandhi Centre for Biotechnology in Thiruvananthapuram, a nodal organization to study the novel coronavirus, put us through exacting tests. We got a 99.99% kill rate on SARS-CoV-2 repeatedly," says Anandkumar. Tests at C-CAMP and University of South Florida showed the mask kills other flu viruses and disease-causing bacteria, apart from the covid-19 virus.
The way the masks IS 212 molecule works is similar to how soap and alcohol destroy the covid-19 virus. Within minutes it ruptures the lipid envelope of the virus, which makes it unstable. Once you rupture the virus envelope, the RNA or genetic material gets exposed, making the virus inactive," explains Sathyanarayanan.
This is unlike a drug which targets the virus itself to stop it from attaching to a host or slow its replication. The virus needs a lipid envelope to survive. Rupturing that is one strategy to prevent its spread.
The I Shield team went through hundreds of molecules to see which were best at rupturing the virus envelope. The next requirement was to bind it to a fabric in an affordable and scalable way, which made IS 212 the best candidate. Another molecule had better activity, but it involved many more steps for synthesis which made it costly," says Sathyanarayanan.
The next step was clearance from the South India Textile Research Association (SITRA), a government-accredited body for testing and certification of products as safe for people to use. Although SITRA has cleared the mask for public use, further certification will be required for it to be deemed medical grade for use in hospitals.
Weve started a parallel process to get it classified and certified as a medical device," says Vohra. For now, I Shield is going to market for everyday use of its mask.
The masks are manufactured by subcontractors in Bengaluru. One of I Shields founding directors is Hitesh Topiwala, owner of Paramount Cosmetics, who is looking at manufacturing and distribution.
I Shield is exploring various channels to scale up availability. We are in talks with one of the largest mask manufacturers in India to see if they will buy our tekFABRIK and use their own brand on the masklike the concept of Intel Inside," says Vohra.
The mask is currently priced at 199 a piece. Other options are on the anvil, such as a crowdfunding campaign. The team has been talking with the government and Niti Aayog to see if public sector production facilities can be roped in to make a version available for around 50, possibly with tweaks in the current six-layered design.
The masks are just a starting point. Other uses of the IS 212 molecule are in the pipeline. For example, it could be used on cab or airplane seats. We have engineered linkers that can bind it to plastic, glass, metal and wood. They can stay bound to surfaces for three or four days, unlike ethanol-based disinfectants which evaporate in minutes," says Sathyanarayanan.
While the main mode of transmission of the covid-19 virus appears to be saliva or mucus droplets, touching infected surfaces is a significant contributor. So we can imagine a scenario where all kinds of surfaces, including our backpacks, would need to be coated with a killer fabric.
Swiss rivals
Swiss company Livinguard has come out with antiviral masks that researchers at Free University of Berlin tested on coronavirus. The companys website says it was tested to neutralize HCoV-229E, a generally accepted surrogate for SARS-CoV-2". The way it works appears similar to I Shieldthe differences will be in price, availability, and certification for efficacy against SARS-CoV-2. HeiQ is another Swiss company licensing its antiviral technology to textile manufacturers.
The Indian governments interest in I Shield comes from its technology having been developed in India with certificates from accredited labs locally as well as abroad, says Anandkumar who has been involved with parleys with officials. A local supply chain opens avenues for mass production at affordable price points within the country.
When Anandkumar got together with Vohra a few years ago to create a biotech incubator, anti-pollution masks were one of their projects. That was the genesis of I Shield but it went on the backburner.
Then covid-19 arrived. We had a bunch of nerdy scientists, so we turned up the heat on the science behind masks," says Anandkumar. We used screening techniques, pulled out a commercial molecule and found a smart way to covalently bind it to a cotton substrate."
Cotton makes the mask comfortable to use in India. The binding keeps the covid-killer molecule attached to the fabric through multiple washes. In lab tests, its efficacy reduced by 2% in 30 washes and 5% in 70 washes," says Sathyanarayanan. Disposal of used masks is a hazard because they carry the virus. Thats another problem these masks solve.
Mass availability and certification for use by healthcare personnel are the next milestones to cross for an Indian product with potential to have a significant impact on the spread of covid-19.
Sumit Chakraberty is a Consulting Editor with Mint. Write to him at chakraberty@gmail.com
Subscribe to newsletters
* Enter a valid email
* Thank you for subscribing to our newsletter.
More:
Now, local masks that claim to kill the covid-19 virus - Livemint
- Podcast 9 Athens part 3 and news - November 8th, 2009 [November 8th, 2009]
- Podcast 10 Athens part 4 - November 8th, 2009 [November 8th, 2009]
- Podcast 11 Athens Part 5 - November 8th, 2009 [November 8th, 2009]
- Episode 12 Cardiac Nuclear Medicine in the UK - November 8th, 2009 [November 8th, 2009]
- Podcast 13 Choline PET and prostate cancer - November 8th, 2009 [November 8th, 2009]
- Episode14 ED function and Dysponea - November 8th, 2009 [November 8th, 2009]
- ep 15 Collimator Choice and Reconstruction algorithm - November 8th, 2009 [November 8th, 2009]
- Episode 16 Dr Strauss on vulnerable plaque - November 8th, 2009 [November 8th, 2009]
- Episode17 Chemical Stress - November 8th, 2009 [November 8th, 2009]
- Episode 18 Myocardial Perfusion Imaging and Diabetes - November 8th, 2009 [November 8th, 2009]
- Episode 19 The INSPIRE trial - November 8th, 2009 [November 8th, 2009]
- 20 Dual isotope with a difference - November 8th, 2009 [November 8th, 2009]
- Episode 21 The real effect of stress - November 8th, 2009 [November 8th, 2009]
- Episode 22 D-SPECT - November 8th, 2009 [November 8th, 2009]
- Episode 23 VQ Reprise - November 8th, 2009 [November 8th, 2009]
- Episode 24 Hepatobiliary Nuclear Medicine - November 8th, 2009 [November 8th, 2009]
- Episode 25 Sleep Apnea - November 8th, 2009 [November 8th, 2009]
- Episode 26 Imaging Post Traumatic Stress Disorder - November 8th, 2009 [November 8th, 2009]
- Episode 27 Cardiac Stem Cells - November 8th, 2009 [November 8th, 2009]
- Episode 28 Molly Supply - November 8th, 2009 [November 8th, 2009]
- Episode 29 Melanoma therapy interview with Dr Ekaterina Dadachova - November 8th, 2009 [November 8th, 2009]
- Episode 30 Viral Therapy - November 8th, 2009 [November 8th, 2009]
- Episode 31 breast radiotherapy using radioisotopes - November 8th, 2009 [November 8th, 2009]
- Episode 32 news from snm - November 8th, 2009 [November 8th, 2009]
- Episode 33 EBV Imaging and Therapy - November 8th, 2009 [November 8th, 2009]
- Episode 34 Dr Lele SNM India 2009 - December 14th, 2009 [December 14th, 2009]
- Episode 35 Dr Andrew Scott from the Ludwig institute - January 10th, 2010 [January 10th, 2010]
- Episode 36 CardiArc - February 25th, 2010 [February 25th, 2010]
- Episode 37 Dr Modder Radiosynoviorthesis (Radiation Synovectomy) - March 31st, 2010 [March 31st, 2010]
- Episode 38 Indian Nuclear Medicine With Dr Malhotra and Dr Krishna - May 28th, 2010 [May 28th, 2010]
- Episode 39 Prof Ora Israel The Utility of Hybrid Imaging - July 13th, 2010 [July 13th, 2010]
- Episode 40 New V/Q SPECT developments - October 11th, 2010 [October 11th, 2010]
- Episode 41 scintimun - February 14th, 2011 [February 14th, 2011]
- Episode 42 Radio-Isotope Supply into the future - March 6th, 2011 [March 6th, 2011]
- Podcast 4: DNA therapy - April 24th, 2011 [April 24th, 2011]
- Sorry about the delay a new podcast will be out soon! - April 24th, 2011 [April 24th, 2011]
- Podcast 5 Flash 3D - April 24th, 2011 [April 24th, 2011]
- Podcast 6 Affibody - April 24th, 2011 [April 24th, 2011]
- Podcast 7 EANM 2006 Athens Part 1 - April 24th, 2011 [April 24th, 2011]
- Podcast 8 Athens Part 2 - April 24th, 2011 [April 24th, 2011]
- Episode 43 Rapidscan Part 1, 720P high quality video version - May 1st, 2011 [May 1st, 2011]
- Episode 43 Rapidscan Part 1, Ipod quality video - May 1st, 2011 [May 1st, 2011]
- Episode 43 Rapidscan Part 1, Audio version - May 1st, 2011 [May 1st, 2011]
- Episode 45 Mummies with cardiovascular disease video - May 21st, 2011 [May 21st, 2011]
- Episode 45 Mummies with cardiovascular disease audio edition - May 21st, 2011 [May 21st, 2011]
- Episode 46 Dr Gordon DePuey Choosing Reconstruction clinical perspective - August 7th, 2011 [August 7th, 2011]
- Episode 46 Dr Gordon DePuey Choosing Reconstruction clinical perspective audio version - August 7th, 2011 [August 7th, 2011]
- Episode 47 Cardiac Image Fusion With Dr Kaufmann - September 18th, 2011 [September 18th, 2011]
- Episode 47 Cardiac Fusion with Dr Kaufmann video version - September 18th, 2011 [September 18th, 2011]
- Dear Steve, I am and many more like me are your one more thing. - October 9th, 2011 [October 9th, 2011]
- EPISODE 48 PET MRI camera from Siemens with Dr Georgi audio - October 23rd, 2011 [October 23rd, 2011]
- EPISODE 48 PET MRI camera from Siemens Dr Georgi video - October 23rd, 2011 [October 23rd, 2011]
- Silicon Biosystems to Present Single-Circulating Tumor Cell Molecular Characterization at the Fourth World CTC Summit - April 25th, 2012 [April 25th, 2012]
- Leukaemia cells have a remembrance of things past - April 25th, 2012 [April 25th, 2012]
- Technologist Education Requirements Can Help Cut Repeat Scans - April 25th, 2012 [April 25th, 2012]
- HKU Collaborative Research Discovers A Novel Molecular Mechanism Of A New Anti-HIV-1 Drug Candidate - April 25th, 2012 [April 25th, 2012]
- Focal Segmental Glomerulosclerosis and the Nephrotic Syndrome - Part 1 Clinical - Video - May 4th, 2012 [May 4th, 2012]
- Electro-Medicine : Biological Physics - The Molecular Basis of Alzheimers Disease - Video - May 4th, 2012 [May 4th, 2012]
- osdd heterocyclic compounds and molecular medicines - Video - May 4th, 2012 [May 4th, 2012]
- Molecule to Medicine: The Biomarker Frontier - Video - May 4th, 2012 [May 4th, 2012]
- Fulfilling the Promise of Molecular Medicine in a Developmental Brain Disorder - Video - May 4th, 2012 [May 4th, 2012]
- Focus on Stefanie Dimmeler - Video - May 4th, 2012 [May 4th, 2012]
- Dundee - May 4th, 2012 [May 4th, 2012]
- Nanotechnology In Medicine: Huge Potential, But What Are The Risks? - May 5th, 2012 [May 5th, 2012]
- Cutting Edge Technology Coming To DMH - May 5th, 2012 [May 5th, 2012]
- This Week in Experimental and Molecular Pathology - May 5th, 2012 [May 5th, 2012]
- Researchers' discovery offers hope for cancer, heart disease miracle drugs - May 7th, 2012 [May 7th, 2012]
- Penn State student Zachary Hostetler from Garnet Valley is being honored as a student marshal - May 7th, 2012 [May 7th, 2012]
- NCKU Student Wins Prestigious Award for Anti-Cancer Research - May 10th, 2012 [May 10th, 2012]
- In-Vitro Diagnostics (IVD) Market (Clinical Chemistry, Immunoassays, Molecular Diagnostics, Hematology Analyzers ... - May 10th, 2012 [May 10th, 2012]
- Pitt team uses genomics to identify a molecular-based treatment for a viral skin cancer - May 10th, 2012 [May 10th, 2012]
- Genomics used to identify a molecular-based treatment for a viral skin cancer - May 10th, 2012 [May 10th, 2012]
- 2 molecular biologists get $500K medical prize - May 13th, 2012 [May 13th, 2012]
- 2 molecular biologists share $500K medical prize - May 13th, 2012 [May 13th, 2012]
- Lab21 Unveils New Molecular Analysis Services at Greenville Site - May 13th, 2012 [May 13th, 2012]
- 2 molecular biologists from NYC to share $500K medical prize for pioneering research on cells - May 13th, 2012 [May 13th, 2012]
- Two Molecular Biologists Get $500K Medical Prize - May 13th, 2012 [May 13th, 2012]
- Pair of molecular biologists receive Albany Medical Center Prize - May 13th, 2012 [May 13th, 2012]
- CNIO scientists successfully test the first gene therapy against aging-associated decline - May 16th, 2012 [May 16th, 2012]
- Cancer Institute of New Jersey Aims to Advance Personalized Cancer Treatments Through 'Precision Medicine' - May 16th, 2012 [May 16th, 2012]